There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Daniel Mikol |
| Institution: | Nervgen |
| Department: | Clinical Development |
| Country: | |
| Proposed Analysis: | At Nervgen we are developing a potentially neurorestorative drug in AD, NVG-291 which targets protein tyrosine phosphatase sigma (PTPs); when PTPs engages chondroitin sulfate proteoglycans in disease states, PTPs is activated, which inhibits repair. NVG-291 modulates PTPs and thereby enables repair. In animals, relevant mechanisms of action of NVG-291 include: enhanced plasticity, axonal regeneration and remyelination, as well as promotion of an anti-inflammatory microglial phenotype; functional improvements have been observed in different animal models. We are currently working on the optimal study design for a proof-of-concept study, which will start in 2022. The goal of ADNI data analysis is to select the optimal imaging modality that is sensitive to improved cognition as a result of improved connectivity. We would like to compare effect sizes of the following imaging modalities in controls vs. patients with MCI: Resting state functional MRI (BOLD); FDG-PET; ASL-perfusion; AVLT; paragraph recall, and ADAS-COG |
| Additional Investigators |
